Ibrutinib targets mutant-EGFR kinase with a distinct binding conformationAoli Wang, Qingsong Liu|Oncotarget|2016Cited by 47
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignanciesHusheng Mei, Qingsong Liu, Hong Wu et al.|Signal Transduction and Targeted Therapy|2023Cited by 46
Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world studyS. Fan, Liangdan Sun, Li Zhang et al.|Journal of Bio-X Research|2020Cited by 20
Discovery of dihydropyridinone derivative as a covalent EZH2 degraderBin Zhou, Beilei Wang, Fengming Zou et al.|European Journal of Medicinal Chemistry|2023Cited by 11